Liquidia Analysts Raise Their Forecasts Following Q2 Results

Liquidia Corporation (NASDAQ:LQDA) reported a loss for the second quarter on Tuesday.

The company posted a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents. Sales reached $8.84 million compared to the consensus of $3.86 million.

In its second-quarter earnings release, the company said that in July and August 2025 it analyzed interim data from the 52-week, prospective, open-label ASCENT study, which fully enrolled 54 patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said, “The second quarter was a defining period for Liquidia with the FDA approval and rapid commercial launch of YUTREPIA™ (treprostinil) inhalation powder. ...